JP7018387B2 - 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 - Google Patents

腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 Download PDF

Info

Publication number
JP7018387B2
JP7018387B2 JP2018519323A JP2018519323A JP7018387B2 JP 7018387 B2 JP7018387 B2 JP 7018387B2 JP 2018519323 A JP2018519323 A JP 2018519323A JP 2018519323 A JP2018519323 A JP 2018519323A JP 7018387 B2 JP7018387 B2 JP 7018387B2
Authority
JP
Japan
Prior art keywords
cells
transduced
cxcr6
nucleic acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018519323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531016A6 (ja
JP2018531016A5 (https=
JP2018531016A (ja
Inventor
ゼバスティアン コボルト，
シュテファン エンドレス，
モーリッツ ラップ，
ジーモン グラスマン，
Original Assignee
ルードヴィッヒ－マクシミリアン－ユニヴェルシタート ミュンヘン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルードヴィッヒ－マクシミリアン－ユニヴェルシタート ミュンヘン filed Critical ルードヴィッヒ－マクシミリアン－ユニヴェルシタート ミュンヘン
Publication of JP2018531016A publication Critical patent/JP2018531016A/ja
Publication of JP2018531016A6 publication Critical patent/JP2018531016A6/ja
Publication of JP2018531016A5 publication Critical patent/JP2018531016A5/ja
Priority to JP2021162481A priority Critical patent/JP2022008805A/ja
Application granted granted Critical
Publication of JP7018387B2 publication Critical patent/JP7018387B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4219—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Output Control And Ontrol Of Special Type Engine (AREA)
JP2018519323A 2015-10-16 2016-10-14 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞 Active JP7018387B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021162481A JP2022008805A (ja) 2015-10-16 2021-10-01 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15190179 2015-10-16
EP15190179.0 2015-10-16
PCT/EP2016/074644 WO2017064222A1 (en) 2015-10-16 2016-10-14 Cxcr6-transduced t cells for targeted tumor therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021162481A Division JP2022008805A (ja) 2015-10-16 2021-10-01 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞

Publications (4)

Publication Number Publication Date
JP2018531016A JP2018531016A (ja) 2018-10-25
JP2018531016A6 JP2018531016A6 (ja) 2018-12-13
JP2018531016A5 JP2018531016A5 (https=) 2019-11-28
JP7018387B2 true JP7018387B2 (ja) 2022-02-10

Family

ID=54359823

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018519323A Active JP7018387B2 (ja) 2015-10-16 2016-10-14 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞
JP2021162481A Pending JP2022008805A (ja) 2015-10-16 2021-10-01 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021162481A Pending JP2022008805A (ja) 2015-10-16 2021-10-01 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞

Country Status (8)

Country Link
US (1) US11723922B2 (https=)
EP (1) EP3362569B1 (https=)
JP (2) JP7018387B2 (https=)
AU (2) AU2016336868B2 (https=)
CA (1) CA3001507C (https=)
DK (1) DK3362569T3 (https=)
ES (1) ES2895901T3 (https=)
WO (1) WO2017064222A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018223211B2 (en) * 2017-02-21 2025-02-27 Adelaide university T cells expressing chemokine receptors for treating cancer
BR112019020909A2 (pt) * 2017-04-05 2020-05-12 Korea Research Institute Of Bioscience And Biotechnology Proteína de fusão ativadora de célula nk, célula nk e composição farmacêutica incluindo a mesma
WO2019113132A1 (en) * 2017-12-05 2019-06-13 Caribou Biosciences, Inc. Modified lymphocytes
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
CN116333995A (zh) * 2020-07-14 2023-06-27 广州泛恩生物科技有限公司 基于cxcr6阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
CN113736740A (zh) * 2021-07-27 2021-12-03 天津市肿瘤医院（天津医科大学肿瘤医院） 胰腺癌稳转细胞系及其构建方法和应用
WO2023158997A2 (en) * 2022-02-15 2023-08-24 Memorial Sloan-Kettering Cancer Center Compositions including killer innate-like t cells and uses therof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076694A1 (en) 1997-07-17 2002-06-20 Littman Dan R. G-coupled receptors associated with retroviral entry into cells, and therapeutic uses thereof
US20140271635A1 (en) 2013-03-16 2014-09-18 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2015028444A1 (en) 2013-08-26 2015-03-05 Universität Zu Köln Anti cd30 chimeric antigen receptor and its use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19822115B4 (de) 1998-05-08 2004-04-08 Heinrich-Pette-Institut Retrovirale Gentransfervektoren
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
US20110280894A1 (en) 2008-07-31 2011-11-17 Angela Krackhardt Her2/neu specific t cell receptors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2694549B1 (en) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
US9359447B2 (en) 2012-03-23 2016-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076694A1 (en) 1997-07-17 2002-06-20 Littman Dan R. G-coupled receptors associated with retroviral entry into cells, and therapeutic uses thereof
US20140271635A1 (en) 2013-03-16 2014-09-18 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2015028444A1 (en) 2013-08-26 2015-03-05 Universität Zu Köln Anti cd30 chimeric antigen receptor and its use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Journal of Immunology (2008), Vol.181, pp.3099-3107
Journal of Virology (2005), Vol.79, No.3, pp.1686-1700
Nature (1997), Vol.388, pp.296-300
Oncotarget (Mar.29, 2015), Vol.6, No.16, pp.14165-14178

Also Published As

Publication number Publication date
EP3362569A1 (en) 2018-08-22
AU2016336868A1 (en) 2018-03-15
JP2022008805A (ja) 2022-01-14
CA3001507A1 (en) 2017-04-20
US11723922B2 (en) 2023-08-15
WO2017064222A1 (en) 2017-04-20
DK3362569T3 (da) 2021-10-18
AU2016336868B2 (en) 2022-04-14
US20180256645A1 (en) 2018-09-13
AU2022205240A1 (en) 2022-09-29
ES2895901T3 (es) 2022-02-23
JP2018531016A (ja) 2018-10-25
CA3001507C (en) 2023-09-19
EP3362569B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
JP7018387B2 (ja) 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞
US11090335B2 (en) Chimeric antigen receptor targeting human NKG2DL and methods of preparing said receptor and pharmaceutical composition
RU2688185C2 (ru) Способ и композиции для клеточной иммунотерапии
JP5097856B2 (ja) サイトカイン誘導キラー細胞の製造方法
JP2018531016A6 (ja) 腫瘍標的療法のためのｃｘｃｒ６形質導入ｔ細胞
CN112877291A (zh) 基因修饰的t细胞产品、其制备方法和用途
JP2011517944A (ja) 新規に単離された細胞の治療組成物の操作および送達
CN107106609A (zh) 刺激和扩展t细胞的组合物和方法
AU2006298188A1 (en) Method for production of T cell population
JP2022512450A (ja) Ｇｐｃ３を標的とする免疫エフェクター細胞およびその応用
TW202140790A (zh) 病毒載體轉導細胞的方法
HK40093010A (zh) 涉及car工程化t细胞和细小病毒h-1的癌症疗法
EP3935151A1 (en) Ccr8 expressing lymphocytes for targeted tumor therapy
HK1193431A (en) Method and compositions for cellular immunotherapy
HK1193431B (en) Method and compositions for cellular immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211001

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211118

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220131

R150 Certificate of patent or registration of utility model

Ref document number: 7018387

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250